Gastrointestinal bleeding under dabigatran
نویسندگان
چکیده
منابع مشابه
Dabigatran, bleeding, and the regulators.
Dabigatran was the first drug across the finish line in the global race to develop a new and better replacement for the five decade old anticoagulant warfarin. An important indication was long term treatment to reduce the risk of stroke in patients with non-valvular atrial fibrillation. This vulnerable older group, mostly over age 75, number many millions worldwide. The main risk of treating at...
متن کاملDabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...
متن کاملRisk of Gastrointestinal Bleeding Among Dabigatran Users – A Self Controlled Case Series Analysis
This article aims to evaluate the real world risk of gastrointestinal bleeding among users naïve to dabigatran. We adopted a self-controlled case series design. We sampled 1215 eligible adult participants who were continuous insured users between July 1, 2010 and March 31, 2012 with use of dabigatran and at least one gastrointestinal bleeding episode. We used a conditional Poisson regression to...
متن کاملGastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
BACKGROUND/AIMS The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran. METHODS We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals. RESUL...
متن کاملSafety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
The recent introduction of direct oral anticoagulants, including rivaroxaban, dabigatran, apixaban, and edoxaban, for the acute treatment and secondary prevention of venous thromboembolism and in atrial fibrillation has been shown to provide greater clinical benefit than oral vitamin K antagonists. However, direct oral anticoagulants are associated with adverse events, the most common being maj...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Postgraduate Medicine
سال: 2014
ISSN: 0022-3859
DOI: 10.4103/0022-3859.132343